Empagliflozin helps lower diastolic pulmonary artery pressure in patients who have heart failure with either reduced ejection fraction or preserved ejection fraction, regardless of diabetes status, according to results of the EMBRACE HF trial. Pressures were monitored remotely in patients who had an existing implanted device.

“We saw an early, significant effect on lowering pulmonary artery diastolic pressure that became apparent within a few weeks and continued to widen over time,” said Mikhail Kosiborod, MD, Saint Luke’s Mid America Heart Institute, Kansas City, MO.

Pulmonary artery pressure is a strong predictor of clinical status, hospitalizations and death that had not previously been examined with sodium-glucose cotransporter 2 (SGLT2) inhibitors in this context, he added.

Read the full article on TCTMD: EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

Read more >

Related Content

  • Person, Hair, Nurse, Face, Female, Word
    Nicole's story

    "What we do is so vital. We have so much power as nurses." Nicole Roberson, Registered Nurse, Neuroscience ICU, Saint Luke's Hospital of Kansas City

    Read more >
  • Person, Doctor, Clothing, Apparel, Lab Coat, Coat, Face, Nurse
    Deb's story

    Deb Day, Registered Nurse · Anderson County Hospital "I am a Saint Luke's Nurse.  Nurses are the lifeblood of Saint Luke’s compassionate care, and the life-changing work they do is...

    Read more >
  • Apparel, Clothing, Coat, Lab Coat, Person, Doctor
    Danielle's story

    "You get those rare moments that you're reminded why you went into this field, and it makes everything so much better." Danielle Hammontree, Certified Family Nurse Practitioner, Saint Luke’s East Hospital

    Read more >